Protagonist Therapeutics, Inc., a biopharmaceutical company that specializes in developing peptide-based drugs for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, has announced that it is currently working on a number of drugs that are in Phase II clinical trials. These drugs include Rusfertide (PTG-300), an injectable hepcidin mimetic that is being developed for treating erythrocytosis, iron overload, and other blood disorders. The company is also developing JNJ-2113, an orally delivered investigational drug that acts as a biological pathway blocker, and is currently in Phase II clinical trials for treating moderate-to-severe plaque psoriasis. Additionally, Protagonist is working on PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is also in Phase II clinical trials, but for treating inflammatory bowel disease. Protagonist Therapeutics, Inc. has a license and collaboration agreement with Janssen Biotech, Inc. The company, which was founded in 2006, is headquartered in Newark, California.